GlobeNewswire Clinical StudiesOriginal article
Immix Biopharma Announces 89% Complete Response Rate at Interim Update Across All NEXICART-2 Patients, with MRD-Negativity Indicating Potential to Reach up to 98% Complete Response Rate, Supporting Potential Best-in-Class Therapy for Relapsed/Refractory AL Amyloidosis
Data ReadoutpositiveNEXICART-2Positive
AI Analysis
Summary
Immix Biopharma reported positive interim data from NEXICART-2 showing an 89% complete response rate and 100% of new patients achieving either complete response or MRD-negative status, suggesting potential best-in-class efficacy for relapsed/refractory AL amyloidosis.
Clinical Trial Data
Primary Endpoint
Met
Patients
25
Outcome Details
89% complete response rate at interim update; 100% of new patients (25/25) in complete response or MRD-negative status, with 21/25 in CR and 4/25 MRD-negative; potential to reach up to 98% CR
Importance:7/10
Sentiment:
0.85
Phase 2Interim DataComplete ResponseMRD-NegativeAmyloidosisCAR-T
Read the original article
Published by GlobeNewswire Clinical Studies on September 29, 2026 11:00 AM